Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Grübler, MR; Gaksch, M; Kienreich, K; Verheyen, ND; Schmid, J; Müllner, C; Richtig, G; Scharnagl, H; Trummer, C; Schwetz, V; Meinitzer, A; Pieske, B; März, W; Tomaschitz, A; Pilz, S.
Effects of Vitamin D3 on asymmetric- and symmetric dimethylarginine in arterial hypertension.
J Steroid Biochem Mol Biol. 2018; 175:157-163
Doi: 10.1016/j.jsbmb.2016.12.014
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Grübler Martin
- Co-Autor*innen der Med Uni Graz
- Keppel Martin
- Kienreich Katharina
- März Winfried
- Meinitzer Andreas
- Pieske Burkert Mathias
- Pilz Stefan
- Richtig Georg
- Scharnagl Hubert
- Schmid Johannes
- Theiler-Schwetz Verena
- Tomaschitz Andreas
- Trummer Christian
- Verheyen Nicolas Dominik
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND AND AIMS: Accumulating evidence has proposed a correlation between vitamin D (25(OH)D) insufficiency and cardiovascular (CV) disease. Vitamin D associated effects on endothelial function have been suggested to be a possible culprit. The present study investigated the association of vitamin D3 treatment on markers of endothelial dysfunction in patients with arterial hypertension. METHODS AND RESULTS: The Styrian Vitamin D Hypertension Trial is a double-blind, placebo-controlled, single-centre study conducted at the Medical University of Graz, Austria. A total of 200 study participants with arterial hypertension and 25(OH)D levels below 30ng/mL were enrolled. The study participants were randomized to receive 2800 IU of vitamin D3 per day as oily drops (n=100) or placebo (n=100) for a duration of eight weeks. The present study uses an analysis of covariance (ANCOVA) to investigate the effect of vitamin D3 treatment on symmetric (SDMA) and asymmetric dimethylarginine (ADMA). A total of 187 participants (mean [SD] age 60.0 [11.3] years; 47% women; 25(OH)D 21.2 [5.6]ng/mL; mean systolic blood pressure of 131.4 [8.9] mmHg on a median of 2 antihypertensive drugs) completed the trial. Mean treatment effect was -0.004 (95%CI [-0.03 to 0.04]; P=0.819) on ADMA and 0.001 (95%CI [-0.05 to 0.05]; P=0.850) on SDMA. In the subgroup analysis patients with a 25(OH)D concentration <20ng/mL had a significant increase in their log l-arginine/ADMA ratio (mean treatment effect 18.4 95%CI [1.84-34.9]μmol/L/μmol/L; P=0.030). ClinicalTrials.gov Identifier: NCT02136771 EudraCT number: 2009-018125-70 CONCLUSIONS: Vitamin D3 supplementation in hypertensive patients with low 25-hydroxyvitamin D has no significant effect on ADMA and SDMA.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged - administration & dosage
- Analysis of Variance - administration & dosage
- Arginine - analogs & derivatives, blood
- Blood Pressure - drug effects
- Cholecalciferol - administration & dosage
- Dietary Supplements - administration & dosage
- Double-Blind Method - administration & dosage
- Female - administration & dosage
- Humans - administration & dosage
- Hypertension - blood, complications, diet therapy
- Male - administration & dosage
- Middle Aged - administration & dosage
- Vitamin D - analogs & derivatives, blood
- Vitamin D Deficiency - blood, complications, diet therapy
- Find related publications in this database (Keywords)
- Vitamin D deficiency
- Arterial hypertension
- Endocrinology
- Cardiovascular disease
- Endothelial dysfunction
- Vitamin D